| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-3 |
| Number of pages | 3 |
| Journal | American Journal of Kidney Diseases |
| Volume | 75 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2020 |
ASJC Scopus subject areas
- Nephrology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American Journal of Kidney Diseases, Vol. 75, No. 1, 01.2020, p. 1-3.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Extravascular Lung Water Assessment by Ultrasound to Guide Dry Weight Changes
T2 - Ready for Prime Time?
AU - Agarwal, Rajiv
AU - Toto, Robert D.
AU - Weir, Matthew R.
N1 - Funding Information: Rajiv Agarwal, MD, MS, Robert D. Toto, MD, and Matthew R. Weir, MD. This editorial was produced without any direct financial support. Dr Weir is supported by grants R01HL127422, R01HL132372, U01DK106102, and U01DK116095. Dr Agarwal reports personal fees from Relypsa, Inc (a Vifor Pharma Group Company), Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly & Co, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Sandoz, ZS Pharma, Akebia, Takeda, Sanofi, Reata, Ironwood Pharmaceuticals, Otsuka, Opko, and Birdrock Bio, all outside the submitted work; has served as an Associate Editor of the American Journal of Nephrology and Nephrology, Dialysis, and Transplantation and an author for UpToDate; and has received research grants from the US Veterans Administration and National Institutes of Health. Dr Toto reports serving as consultant for Amgen, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Quest Diagnostics, Quintiles, Relypsa, and Reata. Dr Weir reports serving as consultant for Abbvie, Astra-Zeneca, Boehringer-Ingelheim, Merck, Janssen, Relypsa, Vifor, Boston Scientific, and Bayer. Received August 12, 2019, in response to an invitation from the journal. Direct editorial input from an Associate Editor and a Deputy Editor. Accepted in revised form September 8, 2019. Funding Information: Dr Agarwal reports personal fees from Relypsa, Inc (a Vifor Pharma Group Company), Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly & Co, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Sandoz, ZS Pharma, Akebia, Takeda, Sanofi, Reata, Ironwood Pharmaceuticals, Otsuka, Opko, and Birdrock Bio, all outside the submitted work; has served as an Associate Editor of the American Journal of Nephrology and Nephrology, Dialysis, and Transplantation and an author for UpToDate ; and has received research grants from the US Veterans Administration and National Institutes of Health. Dr Toto reports serving as consultant for Amgen, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Quest Diagnostics, Quintiles, Relypsa, and Reata. Dr Weir reports serving as consultant for Abbvie, Astra-Zeneca, Boehringer-Ingelheim, Merck, Janssen, Relypsa, Vifor, Boston Scientific, and Bayer.
PY - 2020/1
Y1 - 2020/1
UR - http://www.scopus.com/inward/record.url?scp=85076174067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076174067&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2019.09.004
DO - 10.1053/j.ajkd.2019.09.004
M3 - Editorial
C2 - 31732236
AN - SCOPUS:85076174067
SN - 0272-6386
VL - 75
SP - 1
EP - 3
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 1
ER -